Search Within

Richard M Steingart

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (16)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (34)
  2. Cardiology (34)
  3. Department of Medicine (34)
  4. Division of Subspecialty Medicine (34)
  5. Epidemiology and Biostatistics (34)
  6. Survivorship Research (32)

More Groups

People
  1. Chau Dang (25)
  2. Anthony Yu (16)
  3. Jennifer Liu (16)
  4. Chaya Moskowitz (14)
  5. Clifford Hudis (14)
  6. Sujata Patil (14)

More People

Years
  1. 2024 (1)
  2. 2023 (5)
  3. 2021 (1)
  4. 2020 (5)
  5. 2019 (2)
  6. 2018 (1)

More Years

Publications
  1. Journal of Clinical Oncology (11)
  2. Journal of the American College of Cardiology (6)
  3. Clinical Cancer Research (2)
  4. JAMA Cardiology (2)
  5. Journal of the American Heart Association (2)
  6. Advances in Radiation Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (11)
  2. Elsevier Science, Inc. (6)
  3. American Association for Cancer Research (3)
  4. American Medical Association (3)
  5. Wiley Blackwell (3)
  6. Biomed Central Ltd (2)

More Publishers

Results (34)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC)
    Meeting Abstract

    Morris, P. G.; Iyengar, N. M.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R. J.; Steingart, R.; Oeffinger, K. C.; Lin, N.; Moy, B.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Morris, P. G.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R. J.; Steingart, R.; Oeffinger, K. C.; Lin, N. U.; Moy, B.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer
    Journal Article

    Morris, P. G.; Iyengar, N. M.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R.; Steingart, R.; Oeffinger, K. C.; Lin, N.; Moy, B.; more...
    Cancer (2013)

    Fulltext@MSK | Save
  • Superiority of 2D myocardial strain imaging in the detection of late-onset treatment related cardiac toxicity in asymptomatic adult survivors of childhood cancer
    Meeting Abstract

    Raikhelkar, J.; Oeffinger, K.; Zabor, E.; Moskowitz, C.; Adsuar, R.; Tonorezos, E.; Steingart, R.; Diaz, R.; Liu, J.
    Journal of the American College of Cardiology (2012)

    Fulltext@MSK | Save
  • Long-term cardiac safety and outcomes of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC)
    Meeting Abstract

    Dang, C. T.; Morris, P. G.; Patil, S.; Chen, C.; Abbruzzi, A.; Lehman, R.; Steingart, R.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib
    Journal Article

    Morris, P. G.; Chen, C.; Steingart, R.; Fleisher, M.; Lin, N.; Moy, B.; Come, S.; Sugarman, S.; Abbruzzi, A.; Lehman, R.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Journal Article

    Mcarthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea
    Journal Article

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Sugarman, S.; Morris, P.; Abbruzzi, A.; Chen, C.; Steingart, R.; Patil, S.; more...
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Evaluation of the correlation of baseline blood pressure (BP) and plasma renin activity (PRA) with bevacizumab (B)-mediated hypertension in patients with early-stage breast cancer
    Meeting Abstract

    Dickler, M. N.; McArthur, H. L.; Nulsen, B.; Patil, S.; Sealey, J.; Laragh, J.; Merali, C.; Steingart, R.; Hudis, C.; Rugo, H.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer
    Meeting Abstract

    Mcarthur, H.; Rugo, H.; Nulsen, B.; Traina, T.; Patil, S.; Zhou, Q.; Steingart, R.; Dang, C.; Park, J.; Moasser, M.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save